FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380301315> ?p ?o ?g. }

• W4380301315 endingPage "727" @default.
• W4380301315 startingPage "717" @default.
• W4380301315 abstract "•We derived and externally validated a model to predict 1-year mortality after LT in patients with ACLF-grade 2 or 3. •Age, BMI, and the presence of diabetes, respiratory failure, and/or circulatory failure predicted death ≤1 year with reasonable accuracy. •In addition, the prior presence of infection, use of renal replacement therapy, and leukocyte count at LT also influenced the median length of stay. •Our scores can help in discussions with patients and care teams when patients are considered “too sick” for LT. Background & Aims Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS). Methods In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan’2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors. Results We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age >50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS. Conclusions The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits. Impact and implications Liver transplantation (LT) may be the only life-saving procedure available to patients with acute-on-chronic liver failure (ACLF), but clinically instability can augment the perceived risk of post-transplant mortality at 1 year. We developed a parsimonious score with clinically and readily available parameters to objectively assess 1-year post-LT survival and predict median length of stay after LT. We developed and externally validated a clinical model called the Sundaram ACLF-LT-Mortality score in 521 US patients with ACLF with 2 or ≥3 organ failure(s) and 120 French patients with ACLF grade 3. The c-statistic was 0.72 in the development cohort and 0.80 in the validation cohort. We also provided an estimation of the median length of stay after LT in these patients. Our models can be used in discussions on the risks/benefits of LT in patients listed with severe ACLF. Nevertheless, the score is far from perfect and other factors, such as patient’s preference and center-specific factors, need to be considered when using these tools. Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS). In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan’2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors. We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age >50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS. The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits." @default.
• W4380301315 created "2023-06-13" @default.
• W4380301315 creator A5005713550 @default.
• W4380301315 creator A5006126958 @default.
• W4380301315 creator A5008445295 @default.
• W4380301315 creator A5009943096 @default.
• W4380301315 creator A5012816472 @default.
• W4380301315 creator A5015924233 @default.
• W4380301315 creator A5016056703 @default.
• W4380301315 creator A5017307697 @default.
• W4380301315 creator A5018722817 @default.
• W4380301315 creator A5023835392 @default.
• W4380301315 creator A5026102384 @default.
• W4380301315 creator A5027383893 @default.
• W4380301315 creator A5030751539 @default.
• W4380301315 creator A5030970274 @default.
• W4380301315 creator A5033617677 @default.
• W4380301315 creator A5033814751 @default.
• W4380301315 creator A5034942083 @default.
• W4380301315 creator A5037817373 @default.
• W4380301315 creator A5038065771 @default.
• W4380301315 creator A5041922787 @default.
• W4380301315 creator A5042319050 @default.
• W4380301315 creator A5045341706 @default.
• W4380301315 creator A5046643881 @default.
• W4380301315 creator A5047324691 @default.
• W4380301315 creator A5050790425 @default.
• W4380301315 creator A5051869253 @default.
• W4380301315 creator A5053234753 @default.
• W4380301315 creator A5054997772 @default.
• W4380301315 creator A5056418724 @default.
• W4380301315 creator A5056754182 @default.
• W4380301315 creator A5057185352 @default.
• W4380301315 creator A5057829814 @default.
• W4380301315 creator A5058696857 @default.
• W4380301315 creator A5062485708 @default.
• W4380301315 creator A5063209347 @default.
• W4380301315 creator A5067234928 @default.
• W4380301315 creator A5076502320 @default.
• W4380301315 creator A5077229757 @default.
• W4380301315 creator A5079085190 @default.
• W4380301315 creator A5079153438 @default.
• W4380301315 creator A5080812590 @default.
• W4380301315 creator A5081058304 @default.
• W4380301315 creator A5086965411 @default.
• W4380301315 creator A5086976314 @default.
• W4380301315 creator A5089089916 @default.
• W4380301315 creator A5089525685 @default.
• W4380301315 creator A5089881531 @default.
• W4380301315 creator A5090659009 @default.
• W4380301315 date "2023-09-01" @default.
• W4380301315 modified "2023-10-14" @default.
• W4380301315 title "The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure" @default.
• W4380301315 cites W1570110859 @default.
• W4380301315 cites W1989852995 @default.
• W4380301315 cites W1997441323 @default.
• W4380301315 cites W2001137775 @default.
• W4380301315 cites W2013033074 @default.
• W4380301315 cites W2017332381 @default.
• W4380301315 cites W2059796825 @default.
• W4380301315 cites W2068122480 @default.
• W4380301315 cites W2073970954 @default.
• W4380301315 cites W2078271269 @default.
• W4380301315 cites W2118765712 @default.
• W4380301315 cites W2119910794 @default.
• W4380301315 cites W2122814955 @default.
• W4380301315 cites W2161743657 @default.
• W4380301315 cites W2569571716 @default.
• W4380301315 cites W2765886208 @default.
• W4380301315 cites W2885157423 @default.
• W4380301315 cites W2904383869 @default.
• W4380301315 cites W2950388170 @default.
• W4380301315 cites W3011597656 @default.
• W4380301315 cites W3012413426 @default.
• W4380301315 cites W3024735897 @default.
• W4380301315 cites W3100305806 @default.
• W4380301315 cites W3119881433 @default.
• W4380301315 cites W3159704317 @default.
• W4380301315 cites W3173952090 @default.
• W4380301315 cites W3175328334 @default.
• W4380301315 cites W3200626500 @default.
• W4380301315 cites W4205350231 @default.
• W4380301315 cites W4205566396 @default.
• W4380301315 cites W4220711634 @default.
• W4380301315 cites W4280534293 @default.
• W4380301315 cites W4281258756 @default.
• W4380301315 cites W4294131928 @default.
• W4380301315 cites W4317738582 @default.
• W4380301315 doi "https://doi.org/10.1016/j.jhep.2023.05.028" @default.
• W4380301315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37315809" @default.
• W4380301315 hasPublicationYear "2023" @default.
• W4380301315 type Work @default.
• W4380301315 citedByCount "4" @default.
• W4380301315 countsByYear W43803013152023 @default.
• W4380301315 crossrefType "journal-article" @default.
• W4380301315 hasAuthorship W4380301315A5005713550 @default.
• W4380301315 hasAuthorship W4380301315A5006126958 @default.
• W4380301315 hasAuthorship W4380301315A5008445295 @default.

• next